MDT

88.75

+2.73%↑

A

116.89

+2.76%↑

VEEV

166.33

-3.59%↓

HQY

81.95

+1.22%↑

TLRY

6.75

+4.65%↑

MDT

88.75

+2.73%↑

A

116.89

+2.76%↑

VEEV

166.33

-3.59%↓

HQY

81.95

+1.22%↑

TLRY

6.75

+4.65%↑

MDT

88.75

+2.73%↑

A

116.89

+2.76%↑

VEEV

166.33

-3.59%↓

HQY

81.95

+1.22%↑

TLRY

6.75

+4.65%↑

MDT

88.75

+2.73%↑

A

116.89

+2.76%↑

VEEV

166.33

-3.59%↓

HQY

81.95

+1.22%↑

TLRY

6.75

+4.65%↑

MDT

88.75

+2.73%↑

A

116.89

+2.76%↑

VEEV

166.33

-3.59%↓

HQY

81.95

+1.22%↑

TLRY

6.75

+4.65%↑

Search

Cytek Biosciences Inc

Suletud

SektorTervishoid

4.67 1.52

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

4.58

Max

4.79

Põhinäitajad

By Trading Economics

Sissetulek

-39M

-44M

Müük

9.8M

62M

Kasumimarginaal

-70.929

Töötajad

702

EBITDA

4M

-263K

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+35.87% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

7. mai 2026

Turustatistika

By TradingEconomics

Turukapital

20M

581M

Eelmine avamishind

3.15

Eelmine sulgemishind

4.67

Uudiste sentiment

By Acuity

50%

50%

168 / 349 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Weak Bullish Evidence

Cytek Biosciences Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

8. apr 2026, 20:44 UTC

Tulu

Costco Reports 11% Growth in March Sales

8. apr 2026, 23:51 UTC

Market Talk

Global Equities Roundup: Market Talk

8. apr 2026, 23:51 UTC

Market Talk

Nikkei May Rise on Hopes for Talks to End Iran War -- Market Talk

8. apr 2026, 23:36 UTC

Market Talk
Uudisväärsed sündmused

Gold Edges Lower on Likely Technical Correction -- Market Talk

8. apr 2026, 22:56 UTC

Market Talk

Ramelius Resources May Downgrade Cost Guidance This Month -- Market Talk

8. apr 2026, 22:45 UTC

Market Talk

Constellation Brands Points to Continuing Challenges Among Hispanic Consumers -- Market Talk

8. apr 2026, 22:17 UTC

Market Talk

Applied Digital Says Its Holding Out for Quality Customers -- Market Talk

8. apr 2026, 21:52 UTC

Uudisväärsed sündmused

A Closer Look at Iran's 10 Demands -- and Which the U.S. Might Accept -- Update

8. apr 2026, 21:24 UTC

Tulu

FedEx Freight Aims for 12% Profit Growth. How That Compares to the Leader. -- Barrons.com

8. apr 2026, 21:01 UTC

Uudisväärsed sündmused

Oil Prices Tumble Despite Conflicting Reports About the Strait of Hormuz -- Barrons.com

8. apr 2026, 20:50 UTC

Market Talk

Energy & Utilities Roundup: Market Talk

8. apr 2026, 20:43 UTC

Omandamised, ülevõtmised, äriostud

Oracle Is Expressing No Opinion and Is Neutral as to Whether Stockholders Should Tender Their Shrs in Response to TRC's Offer >ORCL

8. apr 2026, 20:43 UTC

Omandamised, ülevõtmised, äriostud

Oracle Does Not Endorse TRC's Mini-Tender Offer or the Offer Documentation >ORCL

8. apr 2026, 20:43 UTC

Omandamised, ülevõtmised, äriostud

Oracle: Offer Represents Less Than 0.04% of Outstanding Common Stk >ORCL

8. apr 2026, 20:42 UTC

Omandamised, ülevõtmised, äriostud

Oracle: TRC Offer Is to Purchase Up to 1M Shrs of Common Stk at $140.50/Shr in Cash >ORCL

8. apr 2026, 20:42 UTC

Omandamised, ülevõtmised, äriostud

Oracle Received Notice of Unsolicited Mini-Tender Offer by TRC Dated March 24 >ORCL

8. apr 2026, 20:42 UTC

Omandamised, ülevõtmised, äriostud

Oracle Responds to TRC Cap Mini-Tender Offer

8. apr 2026, 20:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

8. apr 2026, 20:11 UTC

Omandamised, ülevõtmised, äriostud

Intel Corp.: Repurchased 49% Equity Interest in JV Related to Intel's Fab 34 in Ireland >INTC

8. apr 2026, 20:11 UTC

Omandamised, ülevõtmised, äriostud

Intel Corp.: $14.2B Repurchase Price Financed with Cash on Hand and a Bridge Loan of $6.5B >INTC

8. apr 2026, 20:11 UTC

Omandamised, ülevõtmised, äriostud

Intel Corp.: Repurchased JV Stake From Apollo-Managed Funds and Affiliates >INTC

8. apr 2026, 19:44 UTC

Tulu

These Companies Pay 5% Dividend Yields, and They're Hiking Them Too -- Barrons.com

8. apr 2026, 19:16 UTC

Market Talk

Hogs Follow Cutout Prices Lower -- Market Talk

8. apr 2026, 19:02 UTC

Market Talk

Global Energy Roundup: Market Talk

8. apr 2026, 19:02 UTC

Market Talk

Oil Futures Plunge as Cease-Fire Raises Hopes for Restored Supply -- Market Talk

8. apr 2026, 18:58 UTC

Market Talk

U.S. Natural Gas Futures Fall in Line With Slump in Oil -- Market Talk

8. apr 2026, 18:51 UTC

Market Talk

Global Equities Roundup: Market Talk

8. apr 2026, 18:51 UTC

Market Talk

Levi Strauss CEO Says Expanded Offerings, DTC Focus Are Working -- Market Talk

8. apr 2026, 18:14 UTC

Uudisväärsed sündmused

Fed Minutes Suggest a Lengthy Iran War Could Lead to Rate Hikes -- Barrons.com

8. apr 2026, 18:05 UTC

Uudisväärsed sündmused

Oil Prices Continue to Tumble After Cease-Fire Despite Slow Reopening of Strait of Hormuz -- Barrons.com

Võrdlus sarnastega

Hinnamuutus

Cytek Biosciences Inc Prognoos

Hinnasiht

By TipRanks

35.87% tõus

12 kuu keskmine prognoos

Keskmine 6.25 USD  35.87%

Kõrge 7.5 USD

Madal 5 USD

Põhineb 2 Wall Streeti analüütiku instrumendi Cytek Biosciences Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

2 ratings

1

Osta

1

Hoia

0

Müü

Tehniline skoor

By Trading Central

3.7 / 3.8Toetus ja vastupanu

Lühikene perspektiiv

Weak Bullish Evidence

Keskpikk perspektiiv

Bearish Evidence

Pikk perspektiiv

Bearish Evidence

Sentiment

By Acuity

168 / 349 Pingereas Tervishoid

Uudiste sentiment

Neutral

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Keskmine

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Cytek Biosciences Inc

Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; aurora CS systems; amnis imagestream imaging flow cytometers; guava muse cell analyzers; guava easycyte flow cytometers; and orion reagent cocktail preparation systems. The company also provides reagents and kits, including cFluor reagents that are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments, as well as 25-color immunoprofiling assay that provides turnkey solutions for identifying major human immune subpopulations for TBNK cells, monocytes, dendritic cells, and basophils. In addition, it offers automated micro-sampling system and automated sample loader system, an automated loaders to integrate seamlessly into the aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for aurora and northern lights systems; and customer support tools. The company serves pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific regions; and through distributors or sales agents in European, Latin American, and the Middle Eastern countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.
help-icon Live chat